1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Lupin Shifts Its Focus To Complexity With Biosimilars And Specialty Plans On Horizon

As It Reports Highest Margins And US Revenues In Five Years

 
• By Urtė Fultinavičiūtė

While quarterly revenues show ups and downs in each region, Lupin is set on continued growth, with a touch of complexity and innovation – including shifting its thinking on the attractiveness of biosimilars.

Illustration of a person on a ladder. Concept of thinking outside of the box
(Shutterstock)

Just last year, over the course of a couple of quarterly updates, Lupin’s CEO Vinita Gupta said that the firm was taking a “cautious approach” on biosimilars and calling it a “difficult marketplace”. However, it seems that Lupin has changed its mind.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024

 
• By Dave Wallace

With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.

Henlius Builds Profitability Streak With Second Year In The Black

 
• By Adam Zamecnik

The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.

More from Products